HomeORGANIZATION
ORGANIZATION

Broader Approach to HTA Could Be Used to Validate Initial Pricing Premiums: PhRMA HTA Chief
(Apr.26.2017)

David L. Grainger, chair of PhRMA International HTA Task Force
If the Japanese government is to roll out some sort of cost-effective analysis (CEA) scheme for the re-pricing of listed drugs, it could be applied to “validate” correction premiums granted to new drugs in their initial pricing process, David L. Grainger, chair of PhRMA’s International HTA Task Force, told Jiho ...
(LOG IN FOR FULL STORY)

News Calendar